MedTrace Logo

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

NCT06715007 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-03-28

No results posted yet for this study

Summary

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

Conditions

  • Stroke, Ischemic
  • Small Vessel Cerebrovascular Disease
  • White Matter Hyperintensity

Interventions

DRUG

Clopidogrel

Patients will take Clopidogrel

DRUG

Aspirin

Patients will take Rivaroxaban

DRUG

Cilostazol + Isosorbide Mononitrate

Patients will take Cilostazol plus Isosorbide Mononitrate

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • zhaolu wang, MD · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
30 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2025-12-20
Completion
2026-01-20

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06715007 on ClinicalTrials.gov